# Shahram Hejazi

> Shahram Hejazi is a seed investor at BioAdvance (New York) backing Health Care and Medical. See 26 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioAdvance](https://shizune.co/investors/profile/bioadvance)
- Location: New York, United States
- Total investments: 26
- Last investment: Jul 2022
- Lead investor: 19%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/shahram-hejazi

Shahram Hejazi is a Board of Director at Halo Labs. As a Venture Partner with BioAdvance, he is responsible for investments in device, diagnostics and imaging field. Within the BioAdvance portfolio, Shahram Hejazi focuses on working with mid/late-stage molecular imaging, life science tools, and diagnostics companies. He is a Board Member forLeversense LLC, Enzium, Inc., Infrascan, Inc., and Optofluidics, Inc.Previously, Shahram Hejazi was the President of Kodak's life science division (now called Carestream Molecular Imaging), where he had global responsibility for R&D, manufacturing, operations, sales, marketing, and service. While holding this position, Shahram Hejazi led the system business to successful double-digit annual growth and directed the launch of a new imaging agent business.Before Kodak, he was the CEO of Zargis Medical Corporation (an early-stage medical device company that spun-off from Siemens), where he led the company's efforts in areas ranging from raising capital and technology development to completion of several clinical trials, FDA approval, and product launch.Prior to Zargis, Shahram Hejazi was the Head of the Strategic Business Development group at Siemens, responsible for identifying early-stage growth/investment opportunities and new business development in the medical field.Earlier in his career, Shahram Hejazi held R&D management positions within the diagnostic imaging and nanotechnology fields at Kodak and IBM.Shahram Hejazi has authored over 10 scientific publications and has been interviewed by several professional journals on topics related to molecular imaging/diagnostics. He is an FDA Industry Advisory Panel Member for Molecular and Clinical Genetic Devices, an Advisory Board Member for Fox Chase Cancer Center, an independent Board Member for SibTech Inc., an independent Board Member for Bioscan Inc., an Advisor to Integral Molecular Inc, and a previous Board Member for Alpha Innotech Corp. (APNO).Shahram Hejazi has a Ph.D. in electrical engineering with an emphasis in biophysics from SUNY at Buffalo and an executive business education at Stanford University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 38% |
| Medical | 8 | 31% |
| Biotechnology | 6 | 23% |
| mHealth | 2 | 8% |
| Hospital | 2 | 8% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 38% |
| Funding Round | 4 | 15% |
| Series A | 2 | 8% |
| Series B | 2 | 8% |
| Series C | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Halo Labs | Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States. | $7M | Series C | Jul 08, 2022 |  |
| Halo Labs | Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States. | $12M | Series B | Apr 06, 2020 |  |
| Ride Health | Ride Health partners with healthcare organizations and transportation providers to manage transportation benefits, strengthen enterprise transportation programs, and improve access to care and social services for at-risk populations. We blend technology and data with a human approach to break down access barriers and solve some of the biggesttransportation challenges that payers, providers, and life science organizations face. Our platform maps out each patient’s unique needs and preferences for the best ride experience across clinical and social needs, ensuring greater access, improved efficiencies, lower costs, and better outcomes. | $6.2M | Seed | Jan 07, 2020 |  |
| Halo Labs | Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States. |  | Series B | Dec 20, 2018 |  |
| Bainbridge Health | Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pumpmanagement system known as InfusionWare that enables clinicians to manage infusion data in one centralized location. |  | Seed | Jun 15, 2018 |  |
| Oncora Medical | Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology. Founded in 2014, Oncora's intuitive software platform allows for better collection and application of real world data for all healthcare related decisions, for the benefit of the patient. |  | Seed | Sep 18, 2017 |  |
| Genome Profiling | Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for bothgenomic variant call analyses data AND epigenetic data. |  |  | Aug 14, 2017 |  |
| WellTrackONE | WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offera comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data.It was founded in 2012 and headquartered in Hilton Head Island, South Carolina. |  |  | Aug 14, 2017 |  |
| TalexMedical | TalexMedical is the proud producer of Infantear – a revolutionary Class I medical device for the treatment of external ear deformities in newborns. InfantEar is a simple, yet elegant, nonsurgical ear molding system, applied in the outpatient setting, replacing the costly, labor intensive surgical ear procedure. The unique, fully customizable deviceis made of soft materials for increased comfort. Targeted primarily to pediatricians, who can recognize and treat the ear anomaly with one two-week treatment applied to a patient in the first three weeks of life, avoiding the delayed and costly external referral with specialists. This helps us to achieve the Triple Aim of Healthcare – improved results, increased patient satisfaction and decreased cost. |  | Seed | Aug 01, 2017 |  |
| Ride Health | Ride Health partners with healthcare organizations and transportation providers to manage transportation benefits, strengthen enterprise transportation programs, and improve access to care and social services for at-risk populations. We blend technology and data with a human approach to break down access barriers and solve some of the biggesttransportation challenges that payers, providers, and life science organizations face. Our platform maps out each patient’s unique needs and preferences for the best ride experience across clinical and social needs, ensuring greater access, improved efficiencies, lower costs, and better outcomes. |  | Seed | May 01, 2017 |  |

10 of 26 investments shown.

## Co-investors
- [Ben Franklin Technology Partners of Southeastern Pennsylvania](https://shizune.co/investors/profile/ben-franklin-technology-partners-of-southeastern-pennsylvania) — VC Fund, 3 deals together
- [BroadOak Capital Partners](https://shizune.co/investors/profile/broadoak-capital-partners) — VC Fund, 3 deals together
- [Research Corporation Technologies](https://shizune.co/investors/profile/research-corporation-technologies) — VC Fund, 3 deals together
- [StartUp Health](https://shizune.co/investors/profile/startup-health) — VC Fund, 2 deals together
- [500 Global](https://shizune.co/investors/profile/500-startups) — VC Fund, 1 deal together
- [Agilent Technologies](https://shizune.co/investors/profile/agilent) — VC Fund, 1 deal together

## About BioAdvance

VC Fund · Philadelphia, United States

BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health.Since its first investments in 2003, BioAdvance has become one of the nation's leading investorsproviding pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.

5 contacts available at BioAdvance.

| Name | Title | Profile |
| --- | --- | --- |
| Shahram Hejazi | Partner | https://shizune.co/investors/profile/shahram-hejazi |
| Barbara S. Schilberg | Managing Director | https://shizune.co/investors/profile/barbara-s-schilberg |
| Frederick Jones | Partner | https://shizune.co/investors/profile/frederick-jones |
| Gregory Harriman | Partner and Chief Investment Officer | https://shizune.co/investors/profile/gregory-harriman |
| Jeff Edelson | Entrepreneur in Residence / Scientific Liason | https://shizune.co/investors/profile/jeff-edelson |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Shahram Hejazi invest in?

Shahram Hejazi invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Funding Round stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shahram Hejazi last invest?

The most recent investment recorded for Shahram Hejazi closed in Jul 2022. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co